This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mode of action

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is thought to be via competing with oestradiol for a cytoplasmic receptor. Approximately 50% of patients with advanced breast carcinoma are receptor positive and will respond to tamoxifen therapy. There is a response to treatment in about 15% of patients who are receptor negative.

Tamoxifen and its active metabolite desmethyl tamoxifen both have a t1/2 of approximately 2 weeks. A steady state is not reached until at least 6 weeks after commencing therapy.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.